I found the data from phase II of the two BRAF inhibitors and with the caveat of comparing results from different trials, they seem to be in the same ballpark.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.